P-022 - Expression of Circulating Annexin A2 in Hepatic Diseases and Hepatocellular Carcinoma

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Hepatobiliary Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter M. Khalaf
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M. Khalaf1, E. Elgezawy1, M. Eldeen2, L. Abdelbaky1, S. Eldeek1
  • 1Assiut University Hospital, Assiut/EG
  • 2AUH, Assiut/EG



Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancer related mortality worldwide. Aims to assess the value of serum Annexin as non-invasive tool in correlation with histopathology of the liver biopsy in prediction of hepatic fibrosis in chronic viral hepatitis “C” and prospective assessment of the predictive value of Annexin for the diagnosis of significant fibrosis, necrosis and inflammation, to examine it as prognostic biomarker for early diagnosis and monitoring of tumor recurrence of HCC.


It was designed to evaluate the significance of serum annexin as non-invasive marker of hepatic fibrosis in chronic hepatitis “C”, its impact as prognostic biomarker in HCC. 40 patients with chronic hepatitis C disease recruited from outpatient clinics, “group I” patients matched to healthy subjects as control group “II”. They were subjected to full medical history, complete medical examination, abdominal sonography, laboratory investigations and liver biopsies after informed consent.


Serum Annexin was significantly increased in group I compared to group II. In addition, there was a significant correlation of Annexin level with grade of fibrosis despite no correlation with grade of activity. No correlations were found between Annexin levels with AST, ALT and PCR levels of HCV RNA. Significant P values of AST, ALT, and platelets in comparison to controls.


No correlation between PCR levels with grade of fibrosis. No significant correlation between PCR level and ALT, AST level. Annexin is non–diagnostic, non-effective as prognostic biomarker for HCC.